Neurocrine Biosciences (NASDAQ:NBIX) Stock Gets Price Target Bump from Royal Bank Of Canada

Neurocrine Biosciences (NASDAQ:NBIX) had its price objective increased by investment analysts at Royal Bank Of Canada from $187.00 to $190.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The firm currently has an “outperform” rating on the stock. Royal Bank Of Canada‘s price target would suggest a potential upside of 14.67% from the company’s current price.

A number of other equities research analysts have also recently weighed in on the company. TD Cowen increased their price target on Neurocrine Biosciences from $200.00 to $220.00 and gave the company a “buy” rating in a research note on Friday, July 31st. Truist Financial lifted their price objective on shares of Neurocrine Biosciences from $200.00 to $213.00 and gave the stock a “buy” rating in a research report on Monday, August 3rd. UBS Group decreased their price objective on shares of Neurocrine Biosciences from $231.00 to $214.00 and set a “buy” rating on the stock in a report on Tuesday, September 29th. Stifel Nicolaus increased their price objective on shares of Neurocrine Biosciences from $188.00 to $215.00 and gave the company a “buy” rating in a research report on Friday, July 31st. Finally, Wall Street Zen cut shares of Neurocrine Biosciences from a “buy” rating to a “hold” rating in a research note on Sunday, August 9th. One investment analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $201.45.

Neurocrine Biosciences Price Performance

NASDAQ NBIX traded up $20.34 during trading on Tuesday, reaching $165.69. 749,745 shares of the company’s stock were exchanged, compared to its average volume of 1,215,711. The business has a 50 day moving average price of $146.49 and a 200-day moving average price of $147.45. The stock has a market capitalization of $16.84 billion, a P/E ratio of 24.31, a PEG ratio of 0.64 and a beta of 0.36. Neurocrine Biosciences has a fifty-two week low of $122.14 and a fifty-two week high of $186.12.

Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings data on Monday, November 2nd. The company reported $3.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.91 by $1.38. Neurocrine Biosciences had a return on equity of 22.43% and a net margin of 20.91%. The company had revenue of $1.12 billion during the quarter, compared to analysts’ expectations of $1.04 billion. During the same period last year, the firm posted $2.04 earnings per share. The business’s revenue was up 41.3% on a year-over-year basis. On average, analysts forecast that Neurocrine Biosciences will post 7.72 earnings per share for the current year.

Insider Buying and Selling at Neurocrine Biosciences

In other news, insider David W. Boyer sold 826 shares of Neurocrine Biosciences stock in a transaction on Monday, September 14th. The stock was sold at an average price of $157.45, for a total transaction of $130,053.70. Following the completion of the sale, the insider owned 8,722 shares of the company’s stock, valued at approximately $1,373,278.90. This trade represents a 8.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Matt Abernethy sold 2,311 shares of the business’s stock in a transaction dated Monday, September 14th. The shares were sold at an average price of $157.20, for a total transaction of $363,289.20. Following the completion of the sale, the chief financial officer directly owned 42,808 shares of the company’s stock, valued at approximately $6,729,417.60. The trade was a 5.12% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 4.60% of the company’s stock.

Institutional Trading of Neurocrine Biosciences

Hedge funds and other institutional investors have recently bought and sold shares of the business. BlackRock Inc. bought a new position in shares of Neurocrine Biosciences during the second quarter worth approximately $2,310,886,000. Renaissance Technologies LLC boosted its stake in shares of Neurocrine Biosciences by 8.0% in the first quarter. Renaissance Technologies LLC now owns 2,418,897 shares of the company’s stock valued at $318,665,000 after buying an additional 180,100 shares during the period. First Trust Advisors LP grew its position in Neurocrine Biosciences by 97.0% during the first quarter. First Trust Advisors LP now owns 959,217 shares of the company’s stock worth $126,367,000 after buying an additional 472,408 shares in the last quarter. Bank of New York Mellon Corp acquired a new stake in Neurocrine Biosciences during the second quarter worth approximately $117,827,000. Finally, Ieq Capital LLC acquired a new stake in Neurocrine Biosciences during the second quarter worth approximately $107,914,000. Institutional investors and hedge funds own 92.59% of the company’s stock.

Key Neurocrine Biosciences News

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Strong third-quarter performance: Neurocrine reported adjusted earnings of $3.29 per share, well above estimates ranging from $1.91 to $2.67 and up from $2.04 a year earlier. Revenue rose 41.3% year over year to $1.12 billion, exceeding the approximately $1.04 billion consensus. Neurocrine Biosciences Reports Third-Quarter 2026 Financial Results
• Positive Sentiment: Product sales surpassed $1 billion: Management said quarterly net product sales exceeded $1 billion for the first time, reflecting strong demand across its portfolio. The company also raised 2026 net sales guidance for INGREZZA to $2.9 billion-$2.925 billion, reinforcing expectations for continued commercial momentum. Neurocrine Biosciences Crosses $1 Billion in Quarterly Product Sales
• Positive Sentiment: Analysts raised targets: Canaccord Genuity increased its target from $210 to $220 and assigned a “buy” rating, while Piper Sandler raised its target from $210 to $215 and maintained an “overweight” rating. Both targets imply substantial appreciation from the referenced $145.35 share price. Canaccord Genuity Group Recommendations Piper Sandler Recommendations
• Neutral Sentiment: Investor focus is likely to remain on management’s earnings-call commentary regarding demand trends, guidance and the company’s broader product pipeline. No material negative development was reported in the supplied coverage. Neurocrine Q3 2026 Earnings Call Transcript

About Neurocrine Biosciences

Neurocrine Biosciences, Inc is a San Diego-based biopharmaceutical company focused on discovering, developing and commercializing medicines for neurological, neuroendocrine and psychiatric disorders. The company’s research programs target conditions in which treatments may address significant unmet medical needs.

Neurocrine’s leading product is INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor approved in the United States for the treatment of tardive dyskinesia and chorea associated with Huntington’s disease.